CAD, CPTAC-466 - CPTAC Assay Portal (original) (raw)

Please include the following statement when referencing the CPTAC Assay Portal

We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Protein Sequence hover to view complete sequence

Data source: UniProt

Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node

to view detailed assay information below

All other points link out to UniProt

Phosphorylation Acetylation Ubiquitylation Other

loading

Assay Details for CPTAC-466 Collapse assay details

Data source: Panorama

Official Gene Symbol

CAD

Peptide Sequence

AAFALGGLGSGFASNR

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

556

Peptide End

571

CPTAC ID

CPTAC-466

Peptide Molecular Mass

1,494.7579

Species

Homo sapiens (Human)

Assay Type

Direct MRM

Matrix

cell line lysate pool

Submitting Laboratory

Seoul National University / Korea Institute of Science and Technology and FHCRC

Submitting Lab PI

Youngsoo Kim

Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253

Response curves acquired at Seoul National University / Korea Institute of Science and Technology. Repeatability data acquired at Fred Hutchinson Cancer Research Center.

Response curves acquired at Seoul National University / Korea Institute of Science and Technology. Repeatability data acquired at Fred Hutchinson Cancer Research Center.

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

5500 QTRAP (ABSCIEX)

Internal Standard

peptide

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C,15N

LC

nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)

Column Packing

ChromXP C18-CL, 3 um, 120A

Column Dimensions

150 x 0.075 mm

Flow Rate

500 nL / min

Chromatograms

Data source: Panorama

Response Curves

Data source: Panorama

Retrieving Data

Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y11 (1+) | 18.1 | 11.2 | 19.5 | 29.3 | 17.6 | 30.1 | 34.4 | 20.9 | 35.9 | 15 | 25 | 15 | | y10 (1+) | 36.8 | 14.2 | 29.3 | 42.8 | 19 | 30.7 | 56.4 | 23.7 | 42.4 | 15 | 25 | 15 | | y8 (1+) | 20.1 | 15.9 | 27.1 | 32.4 | 22.4 | 29.5 | 38.1 | 27.5 | 40.1 | 15 | 25 | 15 | | sum | 15.8 | 8.4 | 18.6 | 28.4 | 16.9 | 21.7 | 32.5 | 18.9 | 28.6 | 15 | 25 | 15 |

Additional Resources and Comments

Assay Details for CPTAC-467 Collapse assay details

Data source: Panorama

Official Gene Symbol

CAD

Peptide Sequence

VLGTSPEAIDSAENR

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

1034

Peptide End

1048

CPTAC ID

CPTAC-467

Peptide Molecular Mass

1,557.7635

Species

Homo sapiens (Human)

Assay Type

Direct MRM

Matrix

cell line lysate pool

Submitting Laboratory

Seoul National University / Korea Institute of Science and Technology and FHCRC

Submitting Lab PI

Youngsoo Kim

Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253

Response curves acquired at Seoul National University / Korea Institute of Science and Technology. Repeatability data acquired at Fred Hutchinson Cancer Research Center.

Response curves acquired at Seoul National University / Korea Institute of Science and Technology. Repeatability data acquired at Fred Hutchinson Cancer Research Center.

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

5500 QTRAP (ABSCIEX)

Internal Standard

peptide

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C,15N

LC

nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)

Column Packing

ChromXP C18-CL, 3 um, 120A

Column Dimensions

150 x 0.075 mm

Flow Rate

500 nL / min

Chromatograms

Data source: Panorama

Response Curves

Data source: Panorama

Retrieving Data

Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y11 (1+) | 13.7 | 11.6 | 13.8 | 18.9 | 12.8 | 14.5 | 23.3 | 17.3 | 20 | 15 | 25 | 15 | | y10 (1+) | 12.1 | 7.7 | 5.6 | 11.6 | 7.7 | 6 | 16.8 | 10.9 | 8.2 | 15 | 25 | 15 | | y7 (1+) | 20.1 | 9.8 | 13.2 | 20.1 | 11.8 | 25.8 | 28.4 | 15.3 | 29 | 15 | 25 | 15 | | sum | 8.7 | 5.7 | 5.7 | 10.2 | 6 | 6.2 | 13.4 | 8.3 | 8.4 | 15 | 25 | 15 |

Additional Resources and Comments